Substance Use and Adherence to Antiretroviral Therapy: What Is Known and What Is Unknown

Overview

Journal Curr Infect Dis Rep

Specialty Infectious Diseases

Date 2018 Aug 2

PMID 30066113

Citations 25

Authors

M Eugenia Socias

M-J Milloy

Affiliations

Soon will be listed here.

Abstract

Purpose Of Review: People who use drugs face multiple challenges to achieve optimal HIV treatment outcomes. This review discusses the current knowledge in substance use and antiretroviral therapy adherence, highlighting recent findings and potential interventions.

Recent Findings: Studies continue to demonstrate the negative impacts of substance use and related disorders on antiretroviral therapy adherence, with the exception of cannabis. Evidence-based addiction treatment, in particular, opioid agonist therapy, appears to improve adherence levels. Most individual-level adherence specific interventions did not provide sustained effects, and no studies evaluating structural-level interventions were found. Findings suggest the urgent need to scale-up opioid agonist therapy, as well as to simultaneously address multiple structural barriers to care to optimize HIV treatment outcomes among people who use drugs.

Citing Articles

Acceptability of long-acting antiretroviral therapy among people living with HIV who use drugs in Vancouver, Canada: A qualitative study.

Chayama K, Ng C, Brohman I, Mansoor M, Small W, Philbin M PLoS One. 2025; 20(2):e0319010.

PMID: 40019916 PMC: 11870339. DOI: 10.1371/journal.pone.0319010.

mHealth Engagement for Antiretroviral Medication Adherence Among People With HIV and Substance Use Disorders: Observational Study.

Mi R, Yang E, Tahk A, Tarfa A, Cotter L, Lu L J Med Internet Res. 2024; 26():e57774.

PMID: 39705693 PMC: 11699505. DOI: 10.2196/57774.

Severity and Number of Substances Used are Independently Associated with Antiretroviral Therapy Adherence Over Time among People with HIV in the Current Treatment Era.

Ma J, Delaney J, Ruderman S, Nance R, Hahn A, Drumright L AIDS Behav. 2024; 29(2):468-479.

PMID: 39465466 DOI: 10.1007/s10461-024-04532-7.

On the issue of treating HIV in people with syndemic mental-health and substance-use disorders.

Grelotti D, Montoya J, Delorme-Walker V, Iudicello J, Ellis R, Grant I Nat Ment Health. 2024; 2(8):879-880.

PMID: 39211438 PMC: 11360833. DOI: 10.1038/s44220-024-00283-5.

Adherence to antiretroviral therapy among cisgender gay, bisexual and other men who have sex with men in Brazil: Evaluating the role of HIV-related stigma dimensions.

Matos V, Torres T, Luz P PLoS One. 2024; 19(8):e0308443.

PMID: 39116156 PMC: 11309385. DOI: 10.1371/journal.pone.0308443.

References

Joseph B, Kerr T, Puskas C, Montaner J, Wood E, Milloy M . Factors linked to transitions in adherence to antiretroviral therapy among HIV-infected illicit drug users in a Canadian setting. AIDS Care. 2015; 27(9):1128-36. PMC: 4830351. DOI: 10.1080/09540121.2015.1032205. View

Viswanathan S, Detels R, Mehta S, Macatangay B, Kirk G, Jacobson L . Level of adherence and HIV RNA suppression in the current era of highly active antiretroviral therapy (HAART). AIDS Behav. 2014; 19(4):601-11. PMC: 4393774. DOI: 10.1007/s10461-014-0927-4. View

Gonzalez A, Barinas J, OCleirigh C . Substance use: impact on adherence and HIV medical treatment. Curr HIV/AIDS Rep. 2011; 8(4):223-34. DOI: 10.1007/s11904-011-0093-5. View

Vidot D, Lerner B, Gonzalez R . Cannabis Use, Medication Management and Adherence Among Persons Living with HIV. AIDS Behav. 2017; 21(7):2005-2013. PMC: 5503453. DOI: 10.1007/s10461-017-1782-x. View

Metsch L, Feaster D, Gooden L, Matheson T, Stitzer M, Das M . Effect of Patient Navigation With or Without Financial Incentives on Viral Suppression Among Hospitalized Patients With HIV Infection and Substance Use: A Randomized Clinical Trial. JAMA. 2016; 316(2):156-70. PMC: 5339876. DOI: 10.1001/jama.2016.8914. View

De Boni R, Shepherd B, Grinsztejn B, Cesar C, Cortes C, Padgett D . Substance Use and Adherence Among People Living with HIV/AIDS Receiving cART in Latin America. AIDS Behav. 2016; 20(11):2692-2699. PMC: 5069110. DOI: 10.1007/s10461-016-1398-6. View

Moore D, Blackstone K, Woods S, Ellis R, Atkinson J, Heaton R . Methamphetamine use and neuropsychiatric factors are associated with antiretroviral non-adherence. AIDS Care. 2012; 24(12):1504-13. PMC: 3466384. DOI: 10.1080/09540121.2012.672718. View

Gonzalez A, Mimiaga M, Israel J, Bedoya C, Safren S . Substance use predictors of poor medication adherence: the role of substance use coping among HIV-infected patients in opioid dependence treatment. AIDS Behav. 2012; 17(1):168-73. PMC: 3632258. DOI: 10.1007/s10461-012-0319-6. View

Hayashi K, Wood E, Kerr T, Dong H, Nguyen P, Puskas C . Factors associated with optimal pharmacy refill adherence for antiretroviral medications and plasma HIV RNA non-detectability among HIV-positive crack cocaine users: a prospective cohort study. BMC Infect Dis. 2016; 16(1):455. PMC: 5002322. DOI: 10.1186/s12879-016-1749-y. View

10.

Low A, Mburu G, Welton N, May M, Davies C, French C . Impact of Opioid Substitution Therapy on Antiretroviral Therapy Outcomes: A Systematic Review and Meta-Analysis. Clin Infect Dis. 2016; 63(8):1094-1104. PMC: 5036913. DOI: 10.1093/cid/ciw416. View

11.

Bezabhe W, Chalmers L, Bereznicki L, Peterson G . Adherence to Antiretroviral Therapy and Virologic Failure: A Meta-Analysis. Medicine (Baltimore). 2016; 95(15):e3361. PMC: 4839839. DOI: 10.1097/MD.0000000000003361. View

12.

Azar P, Wood E, Nguyen P, Luma M, Montaner J, Kerr T . Drug use patterns associated with risk of non-adherence to antiretroviral therapy among HIV-positive illicit drug users in a Canadian setting: a longitudinal analysis. BMC Infect Dis. 2015; 15:193. PMC: 4411762. DOI: 10.1186/s12879-015-0913-0. View

13.

Slawson G, Milloy M, Balneaves L, Simo A, Guillemi S, Hogg R . High-intensity cannabis use and adherence to antiretroviral therapy among people who use illicit drugs in a Canadian setting. AIDS Behav. 2014; 19(1):120-7. PMC: 4289662. DOI: 10.1007/s10461-014-0847-3. View

14.

Lundgren J, Babiker A, Gordin F, Emery S, Grund B, Sharma S . Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection. N Engl J Med. 2015; 373(9):795-807. PMC: 4569751. DOI: 10.1056/NEJMoa1506816. View

15.

Lucas P, Walsh Z . Medical cannabis access, use, and substitution for prescription opioids and other substances: A survey of authorized medical cannabis patients. Int J Drug Policy. 2017; 42:30-35. DOI: 10.1016/j.drugpo.2017.01.011. View

16.

Solomon S, Srikrishnan A, Vasudevan C, Anand S, Kumar M, Balakrishnan P . Voucher incentives improve linkage to and retention in care among HIV-infected drug users in Chennai, India. Clin Infect Dis. 2014; 59(4):589-95. PMC: 4334837. DOI: 10.1093/cid/ciu324. View

17.

Milloy M, Montaner J, Wood E . Incarceration of people living with HIV/AIDS: implications for treatment-as-prevention. Curr HIV/AIDS Rep. 2014; 11(3):308-16. PMC: 4365864. DOI: 10.1007/s11904-014-0214-z. View

18.

Danel C, Moh R, Gabillard D, Badje A, Le Carrou J, Ouassa T . A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa. N Engl J Med. 2015; 373(9):808-22. DOI: 10.1056/NEJMoa1507198. View

19.

Gonzalez-Alvarez S, Madoz-Gurpide A, Parro-Torres C, Hernandez-Huerta D, Ochoa Mangado E . Relationship between alcohol consumption, whether linked to other substance use or not, and antiretroviral treatment adherence in HIV+ patients. Adicciones. 2017; 31(1):8-17. DOI: 10.20882/adicciones.916. View

20.

Milloy M, Kerr T, Bangsberg D, Buxton J, Parashar S, Guillemi S . Homelessness as a structural barrier to effective antiretroviral therapy among HIV-seropositive illicit drug users in a Canadian setting. AIDS Patient Care STDS. 2011; 26(1):60-7. PMC: 3242618. DOI: 10.1089/apc.2011.0169. View